SLX-0528

P1, N=30, Not yet recruiting, Xenthera, Inc. | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jan 2027 --> Jan 2028

P1, N=30, Not yet recruiting, Xenthera, Inc. | Initiation date: May 2023 --> Nov 2023

The backbone of therapy has been gemcitabine and more recently in combination with Nab-paclitaxel or FOLFIRINOX regimens however the incremental gains in survival range from 2-4.5 months 1,2 with a heavy cost of quality of life due to the side effects... RORgT and the IL-17 pathway is a well-recognized target for inflammatory conditions, and increased expression is associated with a worse prognosis for various cancers. XT-0528 is a high-affinity RORgT inverse agonist with a demonstrated reduction in the key inflammatory cytokine IL-17 and a very good safety profile that is a promising agent for pancreatic cancer. Translational work demonstrates increased RORgT expression in human pancreatic cancer and RORgT inhibition led to tumor regression within a human xenograft tumor model.